This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LabCorp (LH) Q2 Earnings Top Estimates, Raises '22 EPS View
by Zacks Equity Research
LabCorp (LH) posts better-than-expected earnings in the second quarter and demonstrates continued strength in the organic Base Business.
Hologic (HOLX) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Hologic (HOLX) reports better-than-expected results in the fiscal third quarter with robust sales performance in the GYN Surgical business.
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.
Thermo Fisher (TMO) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Specialty Diagnostics segment revenues is disappointing.
West Pharmaceutical (WST) Q2 Earnings Beat, FY22 View Cut
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter earnings reflect strength in the Proprietary Products segment.
Merit Medical (MMSI) Q2 Earnings Beat, FY22 View Revised
by Zacks Equity Research
Merit Medical (MMSI), in the second quarter, benefits from revenue growth in both its segments and from all product categories within its Cardiovascular unit.
Neogen (NEOG) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Neogen (NEOG) delivers better-than-expected results for the fiscal fourth quarter, with robust segmental performance driving the top line.
Neogen (NEOG) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 12.50% and 1.25%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Neogen's (NEOG) robust segmental performance and notable product launches instill investors' confidence.
Neogen (NEOG) to Offer New Biosecurity Solution in Canada
by Zacks Equity Research
Neogen's (NEOG) newest addition to the biosecurity portfolio is anticipated to curb the spread of diseases like COVID-19 and avian influenza.
NEOGEN (NEOG) Launches Insecticide for Poultry Producers
by Zacks Equity Research
NEOGEN's (NEOG) insect control solution for poultry producers is the latest addition to the company's Prozap product line.
NEOGEN (NEOG) Introduces InfiniSEEK for Cattle Breeders
by Zacks Equity Research
NEOGEN's (NEOG) recent launch enables simultaneous low-pass whole genome sequencing and high-coverage genotyping at regions of interest.
NEOGEN (NEOG) Adds to Prozap Insect Control Product Line-up
by Zacks Equity Research
NEOGEN's (NEOG) latest Prozap Protectus Pour-On Insecticide- IGR product relieves cattle from infestations.
Neogen's (NEOG) Q3 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Robust segmental performance and contributions from the Soleris product line drive the top line for Neogen (NEOG) in third-quarter of fiscal 2022 results.
Company News for Mar 25, 2022
by Zacks Equity Research
Companies in The News Are: MOMO,NEOG,OLLI,KBH
Neogen (NEOG) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -13.33% and 1.35%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 14.29% and 9.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Onto Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) progress at the Food Safety and Animal Safety segments.
TG Therapeutics (TGTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -12.90% and 76.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 11.66% and 6.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Down 19% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ensign Group (ENSG) Up 7.4% in 3 Months: More Growth Ahead?
by Zacks Equity Research
Ensign Group (ENSG) is likely to keep growing on the back of Skilled services and impressive financial strength.
Select Medical (SEM) '21 Sales View Up, Labor Costs Ail Profits
by Zacks Equity Research
Select Medical Holdings (SEM) estimates net operating revenues for 2021 to be $6.2 billion, up from the previous expectations.
Here's Why You Should Invest in Neogen (NEOG) Stock Now
by Zacks Equity Research
Neogen's (NEOG) better-than-expected Q2 revenues and robust growth across Food Safety & Animal Safety businesses instill investor confidence.
Neogen (NEOG) Q2 Earnings Lag Estimates, Revenues Surpass
by Zacks Equity Research
Robust segmental performance and contributions from StandGuard & Soleris product lines drove the top line for Neogen (NEOG) in the second quarter of fiscal 2022.